IVF used by some to avoid passing on genetic diseases to offspring
Some couples with muscular dystrophy, cystic fibrosis and other such ailments undergo in vitro fertilization and preimplantation genetic testing to find disease-free embryos. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - December 4, 2021 Category: Consumer Health News Authors: Jamie Talan Source Type: news

What are pros and cons of whole-genome sequencing for every UK baby?
Knowing a baby ’s whole genetic code would help detect a range of health problems, but would not replace need for some existing testsScientists raise concerns over UK baby genome sequencing planWhat is the current newborn screening?All babies in the UK are offered the“heel prick” or blood spot test at around five days old to screen for nine serious health conditions, including cystic fibrosis, sickle cell disease and various metabolic diseases. These conditions, if identified, can be treated or managed. Genetic testing is only offered in certain cases, such as if there is a concern that the baby might be ...
Source: Guardian Unlimited Science - December 2, 2021 Category: Science Authors: Hannah Devlin Science correspondent Tags: Genetics Medical research UK news Biology Science Children Society NHS Health Source Type: news

Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT
RCT (n=286) found intravenous antibiotics were not more likely than oral antibiotics to achieve the composite primary outcome of eradication of Pseudomonas aeruginosa infection at 3 months and remaining infection-free at 15 months (RR 0.84, 95% CI 0.65 to 1.09; p=0.184). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 23, 2021 Category: Consumer Health News Source Type: news

St. Louis Character: Sims Executive Search founder Randy Sims on how a double lung transplant gave him a new lease on life
In 1999, Randy Sims received a double lung transplant after a childhood cystic fibrosis diagnosis. Now, he's a business owner, speaker and author, celebrating his 23rd year with his new lungs. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 11, 2021 Category: American Health Authors: Maddy Simpson Source Type: news

Vertex taps California startup for $700M gene-editing deal
Vertex Pharmaceuticals Inc. of Boston will partner with a California startup to develop therapies for two genetic diseases, the companies said Tuesday. Mammoth Biosciences Inc., based in Brisbane, California, will receive $41 million upfront — nearly the same amount of its Series B financing late last year — with the prospect of another $650 million by hitting development, regulatory and commercial milestones. Vertex (NASDAQ: VRTX) has devel oped cystic fibrosis therapies and is working with… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 27, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Vertex taps California startup for $700M gene-editing deal
Vertex Pharmaceuticals Inc. of Boston will partner with a California startup to develop therapies for two genetic diseases, the companies said Tuesday. Mammoth Biosciences Inc., based in Brisbane, California, will receive $41 million upfront — nearly the same amount of its Series B financing late last year — with the prospect of another $650 million by hitting development, regulatory and commercial milestones. Vertex (NASDAQ: VRTX) has devel oped cystic fibrosis therapies and is working with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 27, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic FibrosisBoehringer Ingelheim has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology   Partners aim to expedite the development of the novel, inhaled cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy BI 3720931 as a long-lasting therapeutic option for patients with cystic fibrosis (CF) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 18, 2021 Category: Research Source Type: news

Scientist behind Vertex CF drugs launches new startup with Atlas Venture
Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture. Rectify Pharmaceuticals has ambitious plans to target proteins that affect multiple organ systems including the lungs, liver, gastrointestinal tract, eye and central nervous system. The focus of the new startup are something called ATP-binding cassette (ABC) transporters, which are membrane proteins that are crucial to moving substrates… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 14, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Rare disease company EnBiotix merges with Swiss firm
EnBiotix Inc., a Boston-based biotech focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. Under the terms of the agreement, Polyphor will acquire all of EnBiotix's outstanding capital stock; EnBiotix will in turn acquire the rights to inhaled murepavadin, a potent antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in cystic fibrosis patients, for $10 million . The merger is expected to close in the fourth quarter… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 1, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Rare disease company EnBiotix merges with Swiss firm
EnBiotix Inc., a Boston-based biotech focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. Under the terms of the agreement, Polyphor will acquire all of EnBiotix's outstanding capital stock; EnBiotix will in turn acquire the rights to inhaled murepavadin, a potent antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in cystic fibrosis patients, for $10 million . The merger is expected to close in the fourth quarter… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Specialized CT training helps readers diagnose lung disease
A specialized training program for interpreting thoracic CT images can leve...Read more on AuntMinnie.comRelated Reading: AI algorithm can predict severity, progression of COPD Thoracic radiologists give top tips for CT evaluation of lung parenchyma Thirona launches AI algorithm for cystic fibrosis MinIP reconstructions boost CT's COVID-19 performance Machine learning boosts chest CT's performance (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 25, 2021 Category: Radiology Source Type: news

Cystic fibrosis triple therapy
Thousands of cystic fibrosis patients in England have had their health drastically improved by a “miracle” treatment, allowing one to give birth to a baby, since the NHS made it available one year ago. (Source: NHS Networks)
Source: NHS Networks - August 23, 2021 Category: UK Health Source Type: news

For years, I feared that I’d outlive my daughter. And then science did something amazing.
Cystic fibrosis, a genetic disease that slowly destroys the lungs beginning in childhood, has no cure. After years of work, new treatments are changing the dire prognosis for many. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 14, 2021 Category: Consumer Health News Authors: Abby Alten Schwartz Source Type: news

This Morning viewers praise teen with cystic fibrosis who says dance is a 'drug' that saved his life
Dubbed a real life Billy Elliot, Tom Oakley, 18, from Liverpool, who appeared on This Morning today, fell in love with ballet at the age of seven and describes it as a 'drug' that he cannot live without. (Source: the Mail online | Health)
Source: the Mail online | Health - July 28, 2021 Category: Consumer Health News Source Type: news

A small molecule induces readthrough of cystic fibrosis CFTR nonsense mutations
(University of Alabama at Birmingham) An experimental drug reported in Nature Communications suggests that a " path is clearly achievable " to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic fibrosis patients, as well as patients with other genetic diseases, including Duchenne muscular dystrophy,β-thalassemia and numerous types of cancers, that are also caused by nonsense mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Should the most vulnerable be shielding again - no matter what health chiefs say?
The Cystic Fibrosis Trust, Blood Cancer UK and Kidney Care UK, among others, have called for specific guidance for the most vulnerable after tomorrow's so-called Freedom Day. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2021 Category: Consumer Health News Source Type: news

Ex-Genentech principal scientist, husband plead guilty in trade secrets case; two others charged
The case centers on three blockbuster cancer drugs developed by Genentech as well as a cystic fibrosis treatment and spans the globe. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 8, 2021 Category: American Health Authors: Ron Leuty Source Type: news

A Disposable OPEP Device in Children With Cystic Fibrosis A Disposable OPEP Device in Children With Cystic Fibrosis
A novel daily disposable OPEP device may be as effective as reusable devices while eliminating the need for regular cleaning.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 6, 2021 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Cystic Fibrosis: Overjoyed family opens up about transformed life with wonder drug
AN overjoyed family poses with their new arrival a year after their lives were changed by a cystic fibrosis drug fought for by the Daily Express. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2021 Category: Consumer Health News Source Type: news

Whole genome sequencing of all UK newborns ‘would have public support’
Consultation shows positivity towards screening programme to spot those at heightened risk of certain health conditionsPlans to sequence the whole genome of every newborn in the UK in order to spot those at heightened risk of certain health conditions have been given a boost, with consultations suggesting the approach could have public support.The potential for genomics to improve health was at theheart of the chief medical officer annual report of 2016, with a group of experts convened by Genomics England – a government-owned genetics service – subsequently recommending a research programme to sequence the who...
Source: Guardian Unlimited Science - July 4, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Genetics Science UK news NHS Health Childbirth Sickle cell disease Cystic fibrosis Children's health Source Type: news

Diversity is a Living Thing
p{ margin:10px 0; padding:0; } table{ border-collapse:collapse; } h1,h2,h3,h4,h5,h6{ display:block; margin:0; padding:0; } img,a img{ border:0; height:auto; outline:none; text-decoration:none; } body,#bodyTable,#bodyCell{ height:100%; margin:0; padding:0; width:100%; } .mcnPreviewText{ display:none !important; } #outlook a{ padding:0; } img{ -ms-interpolation-mode:bicubic; } table{ mso-table-lspace:0pt; mso-table-rspace:0pt; } .ReadMsgBody{ width:100%; } .ExternalClass{ width:100%; } p,a,li,td,blockquote{ m...
Source: Johns Hopkins University and Health Systems Archive - June 29, 2021 Category: Nursing Source Type: news

What Types of New Therapies are Available for Cystic Fibrosis?
Discussion Cystic fibrosis (CF) was identified in 1938 by Dr. Dorothy Andersen who described 49 patients with pancreatic insufficiency. Since that time significant achievements in the knowledge about the disease and treatments for patients have changed the mortality from a few months to patients living into middle adulthood or even later. Quality of life for patients and their families and friends has also markedly improved. CF is the classic Mendelian autosomal recessive genetic disorder which is a worldwide disorder but affects people of north European ancestry more often where the main mutation is more common. There are...
Source: PediatricEducation.org - June 28, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
BOSTON--(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 9, 2021 Category: Drugs & Pharmacology Source Type: news

How strengthening the biosimilar marketplace benefits patients
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal antibodies and vaccines. They are used to prevent or treat a variety of diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis and autoimmune disorders.  (Source: The Catalyst)
Source: The Catalyst - May 18, 2021 Category: Pharmaceuticals Tags: FDA Drug Cost Biologics and Biosimilars Source Type: news

Health outcomes differ between UK and US children with cystic fibrosis
(University of Liverpool) A new study led by University of Liverpool researchers has confirmed that children with cystic fibrosis (CF) in the US have better lung function than UK children with the disease. The study suggests that differences do not appear to be explained by early growth or nutrition, but could be linked to differences in the use of early treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 14, 2021 Category: International Medicine & Public Health Source Type: news

SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases JERUSALEM, May 13, 2021 -- (He... Biopharmaceuticals, Venture Capital SpliSense, Cystic Fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news

Antimicrobial prescribing: nebulised liposomal amikacin - evidence summary [ES36], NICE (published 12th May 2021)
This concludes nebulised liposomal amikacin may be an option for treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in combination with other antimicrobial agents in adults with limited treatment options& who do not have cystic fibrosis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news

Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
(University of South Australia) World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 13, 2021 Category: Biology Source Type: news

New study determines cystic fibrosis therapy is safe and effective for young children
(Children's Hospital Colorado) Children ages two to five who have the most common form of cystic fibrosis have not had any modulator treatments available to them until recently. A new study authored by researchers at Children's Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2021 Category: International Medicine & Public Health Source Type: news

Molecular analysis identifies key differences in lungs of cystic fibrosis patients
A team of researchers from UCLA, Cedars-Sinai and the Cystic FibrosisFoundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis.The catalog,described today in the journal Nature Medicine, reveals new subtypes of cells and illustrates how the disease changes the cellular makeup of the airways. The findings could help scientists in their search for specific cell types that represent prime targets for genetic and cell therapies for cystic fibrosis.“This new research has provided us with valuable insights into the cellular makeup of both heal...
Source: UCLA Newsroom: Health Sciences - May 7, 2021 Category: Universities & Medical Training Source Type: news

Molecular analysis identifies key differences in lungs of cystic fibrosis patients
(Cedars-Sinai Medical Center) A team of researchers from UCLA, Cedars-Sinai and the Cystic Fibrosis Foundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 6, 2021 Category: International Medicine & Public Health Source Type: news

Multi-drug resistant infection about to evolve within cystic fibrosis patients
(University of Cambridge) Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients - showing that it can evolve rapidly within an individual during chronic infection. The researchers say their findings highlight the need to treat patients with Mycobacterium abscessus infection immediately, counter to current medical practice. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 29, 2021 Category: Infectious Diseases Source Type: news

Bypassing broken genes
(Penn State) A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases. The method involves inserting a new, fully functional copy of the gene that displaces the mutated gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2021 Category: International Medicine & Public Health Source Type: news

Study aims to improve health of patients with CF across their increasing lifespan
(Medical College of Georgia at Augusta University) People with cystic fibrosis are living better and longer, and now investigators want to further enhance quality and longevity by better understanding the role of nutrition, body composition and exercise in their health across an increasing lifespan. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news

Three - Drug Regimen Treats Cystic Fibrosis in Younger Children
Elexacaftor/tezacaftor/ivacaftor well tolerated in children aged 6 through 11 years with cystic fibrosis and at least one F508del - CFTR allele (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 14, 2021 Category: Respiratory Medicine Tags: Family Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Three-Drug Regimen Treats Cystic Fibrosis in Younger Children
WEDNESDAY, April 14, 2021 -- The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 14, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

< a href= " /news-events/nih-research-matters/sweat-sticker-diagnosing-cystic-fibrosis " > “Sweat sticker” for diagnosing cystic fibrosis < /a >
Researchers created a “sweat sticker” for measuring chloride concentrations in sweat, a sign of cystic fibrosis. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - April 13, 2021 Category: Consumer Health News Source Type: news

Bioengineer wins NIH grant to attack cystic fibrosis
(Rice University) Rice University chemical and biomolecular engineer Xue Sherry Gao wins a prestigious National Institutes of Health R01 grant to develop personalized gene editing techniques for cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2021 Category: International Medicine & Public Health Source Type: news

Cystic Fibrosis: More patients can have wonder drug - hope for hundreds
A WONDER drug that "almost cures" cystic fibrosis can be given to hundreds more English patients. (Source: Daily Express - Health)
Source: Daily Express - Health - April 5, 2021 Category: Consumer Health News Source Type: news

Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis? Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis?
The technology may help clinicians monitor how patients respond to treatment and allow for sweat testing outside of clinical settings, researchers suggest.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - April 2, 2021 Category: Pediatrics Tags: Pediatrics News Source Type: news

A simple sweat test for cystic fibrosis
(Source: ScienceNOW)
Source: ScienceNOW - April 1, 2021 Category: Science Authors: Czajka, C. Tags: twis Source Type: news

Soft " sweat stickers " may streamline diagnosis of cystic fibrosis in children
(American Association for the Advancement of Science) New " sweat stickers " may streamline the early diagnosis of cystic fibrosis by enabling scientists to easily gather and analyze sweat from the skin of infants and children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Dutch medical AI company Thirona launches software for cystic fibrosis
The new algorithm allows for automated analysis of CT scans of patients with the condition. (Source: mobihealthnews)
Source: mobihealthnews - March 31, 2021 Category: Information Technology Tags: AI, Analytics, Predictive analytics, Data and Information Source Type: news

Liesbeth Stoeffler, 61, Runner Kept Going by Rare Lung Treatment, Dies
A machine that acted as an artificial lung kept her eligible for a transplant as she dealt with cystic fibrosis. She went on to compete again in marathons. (Source: NYT Health)
Source: NYT Health - March 26, 2021 Category: Consumer Health News Authors: Richard Sandomir Tags: Cystic Fibrosis Coronavirus (2019-nCoV) Ventilators (Medical) Lungs Running AllianceBernstein Holding LP Austria Manhattan (NYC) Stoeffler, Liesbeth (1959-2021) Transplants Source Type: news

Thirona launches AI algorithm for cystic fibrosis
Software developer Thirona is launching Pragma-AI, a new artificial intelligenc...Read more on AuntMinnie.comRelated Reading: Thirona licenses patent for cystic fibrosis AI software Meet the Minnies 2020 semifinal candidates Thirona, Smart Reporting team up on COVID-19 software Thirona unveils AI software for COVID-19 analysis AI-based CAD accurately detects tuberculosis on chest x-rays (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 25, 2021 Category: Radiology Source Type: news

Therapy for most common cause of cystic fibrosis safe and effective in 6-11
(Ann& Robert H. Lurie Children's Hospital of Chicago) An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann& Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2021 Category: International Medicine & Public Health Source Type: news

Singapore scientists develop novel gene editor to correct disease-causing mutations
(Agency for Science, Technology and Research (A*STAR), Singapore) The Genome Institute of Singapore (GIS) has developed a CRISPR-based gene editor to correct mutations that cause genetic disorders. The C-to-G Base Editor (CGBE) by GIS advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. This invention opens up treatment options for approximately 40 per cent of single-base substitutions associated with human diseases - including cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 11, 2021 Category: Biology Source Type: news

Research reveals how bacteria defeat drugs that fight cystic fibrosis
(The University of Montana) University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis. The research was published Feb. 23, 2021 in the journal Cell Reports. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 26, 2021 Category: Infectious Diseases Source Type: news